Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Callander Discusses Combinations in Multiple Myeloma

Natalie S. Callander, MD
Published: Wednesday, Oct 11, 2017



Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Both the POLLUX and CASTOR trials showed high response rates with the use of triplets that involved daratumumab (Darzalex), says Callander.

Callander adds that combinations with elotuzumab (Empliciti), as well as ixazomib (Ninlaro), have shown excellent results as well.
 
SELECTED
LANGUAGE


Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Both the POLLUX and CASTOR trials showed high response rates with the use of triplets that involved daratumumab (Darzalex), says Callander.

Callander adds that combinations with elotuzumab (Empliciti), as well as ixazomib (Ninlaro), have shown excellent results as well.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x